Cellectis (CLLS) Research & Development (2015 - 2026)

Cellectis' Research & Development history runs 12 years deep, the most recent figure standing at -$27.2 million for Q1 2026.

• On a quarterly basis, Research & Development fell 23.96% year-over-year to -$27.2 million in Q1 2026; TTM through Mar 2026 was -$98.8 million, a 208.63% decrease from a year earlier, with the FY2025 full-year figure at -$93.5 million, down 203.29% from the prior year.
• Research & Development fell to -$27.2 million in Q1 2026 per CLLS's latest filing, from -$24.4 million in the prior quarter.
• Across five years, Research & Development topped out at $160.2 million in Q4 2024 and bottomed at -$27.2 million in Q1 2026.
• The 5-year median for Research & Development is -$23.1 million (2025), against an average of -$2.4 million.
• Across the five-year window, Research & Development surged 801.42% in 2023 and slumped 115.25% in 2025, its largest moves.
• Year by year, Research & Development stood at -$21.4 million in 2022, then jumped by 801.42% to $150.3 million in 2023, then grew by 6.57% to $160.2 million in 2024, then slumped by 115.25% to -$24.4 million in 2025, then declined by 11.26% to -$27.2 million in 2026.
• Per Business Quant, the three latest CLLS Research & Development figures stand at -$27.2 million (Q1 2026), -$24.4 million (Q4 2025), and -$24.1 million (Q3 2025).